Skip to main content
HRES 161 113th Congress House

Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

Introduced: April 15, 2013 Introduced by: Rogers, Harold Republican · Kentucky See on congress.gov
Health Drug safety, medical device, and laboratory regulationDrug, alcohol, tobacco usePrescription drugs
Sign in to write a letter Sign in to watch
This resolution expired with the 113th Congress
It was not agreed to before the 113th Congress (2013–2014) adjourned, so it is no longer active. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Agreed to (House)
Apr 19, 2013
Referred to the Subcommittee on Health.
Apr 15, 2013
Referred to the House Committee on Energy and Commerce.
Apr 15, 2013
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action April 19, 2013

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

 Related & companion bills 1
  • SRES 97 Related bill A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse…
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 4
All 4 Democratic 2 Republican 1
R
Aderholt, Robert B.
Alabama · Apr 15, 2013
 D
Keating, William R.
Massachusetts · Apr 15, 2013
 D
Lynch, Stephen F.
Massachusetts · Apr 15, 2013
WOLF, FRANK
· Apr 15, 2013
Cite this page click to expand
APA
U.S. Congress. (2026). H. Res. 161: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.. 113th Congress. Open America. https://openamerica.io/bill/113-HRES-161/
MLA
"H. Res. 161: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.." 113th Congress, 2026, Open America, https://openamerica.io/bill/113-HRES-161/.
Bluebook (legal)
H. Res. 161, 113th Cong. (2026), https://openamerica.io/bill/113-HRES-161/.
Markdown link
[H. Res. 161: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.](https://openamerica.io/bill/113-HRES-161/)
Report a problem